Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study

다국어 초록 (Multilingual Abstract)

Background: Although many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated.
Methods: We evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naïve type 2 diabetes mellitus patients in a 48-week, double-blind, randomized controlled study that included 349 Korean patients. Our primary goal was to determine the change in HbA1c levels from baseline to end point. Our secondary goal was to evaluate changes in fasting plasma glucose (FPG) levels, body weight, frequency of adverse events, and the proportion of participants achieving target HbA1c levels.
Results: HbA1c levels decreased from 7.8% to 6.9% in the glimepiride group (P<0.001), from 7.9% to 7.0% in the metformin group (P<0.001), and from 7.8% to 7.0% (P<0.001) in the rosiglitazone group. Glimepiride and rosiglitazone significantly increased body weight and metformin reduced body weight during the study period. Symptomatic hypoglycemia was more frequent in the glimepiride group and diarrhea was more frequent in the metformin group.
Conclusion: The efficacy of glimepiride, metformin, and rosiglitazone as antidiabetic monotherapies in drug-naïve Korean type 2 diabetic patients was similar in the three groups, with no statistical difference. This study is the first randomized controlled trial to evaluate the efficacy of commonly-used oral hypoglycemic agents in Korean type 2 diabetic patients. An additional subgroup analysis is recommended to obtain more detailed information.

참고문헌 (Reference)

1 Bell DS, "Type 2 diabetes mellitus: what is the optimal treatment regimen" 116 (116): 23-29, 2004

2 Task Force Team of Korean Diabetes Association, "Treatment guideline for diabetes. 1st ed" Korean Diabetes Association 48-58, 2007

3 Rendell M, "The role of sulphonylureas in the management of type 2 diabetes mellitus" 64 : 1339-1358, 2004

4 Davis SN, "The role of glimepiride in the effective management of type 2 diabetes" 18 : 367-376, 2004

5 Wiernsperger NF, "The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms" 58 (58): 31-39, 1999

6 손태서, "The Effect of Rosiglitazone and Metformin Therapy, as an Initial Therapy, in Patients with Type 2 Diabetes Mellitus" 대한당뇨병학회 32 (32): 445-452, 2008

7 American Diabetes Association, "Standards of medical care in diabetes--2007" 30 (30): 4-41, 2007

8 Lebovitz HE, "Rosiglitazone monotherapy is effective in patients with type 2 diabetes" 86 : 280-288, 2001

9 Meriden T, "Progress with thiazolidinediones in the management of type 2 diabetes mellitus" 26 : 177-190, 2004

10 Riddle MC, "Oral pharmacologic management of type 2 diabetes" 60 : 2613-2620, 1999

11 Cheng AY, "Oral antihyperglycemic therapy for type 2 diabetes mellitus" 172 : 213-226, 2005

12 Stumvoll M, "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus" 333 : 550-554, 1995

13 Kim DJ, "Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus" 50 : 590-593, 2001

14 Kahn SE, "Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy" 355 : 2427-2443, 2006

15 "Global risks 2009: a global risk network report" 2009

16 Yoon KH, "Epidemic obesity and type 2 diabetes in Asia" LANCET LTD 368 : 1681-1688, 200611

17 Hoffmann J, "Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study" 103 : 483-490, 1997

18 Tan M, "Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial" 26 : 680-693, 2004

19 Lebovitz HE, "Differentiating members of the thiazolidinedione class: a focus on safety" 18 (18): 23-29, 2002

20 Chan JC, "Diabetes in Asia: epidemiology, risk factors, and pathophysiology" 301 : 2129-2140, 2009

21 Yamanouchi T, "Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes" 22 : 980-985, 2005